Gilead, US Clash in Billion-Dollar Trial on HIV-Drug Patent

Billions of dollars from Gilead Sciences Inc.’s HIV-prevention drug regimen could ride on whether a federal jury in Delaware agrees with the United States that Gilead, a former research partner, should pay royalties on treatments it alleges infringe three patents.

The trial that kicked off Tuesday is expected to last as long as six days, through May 9, according to preliminary instructions read to the jury Tuesday ahead of opening statements in the US District Court for the District of Delaware.

The US Health and Human Services Department sued Gilead and its Gilead Sciences Ireland UC subsidiary in November 2019, ...